Compare ADMA Biologics Inc (ADMA) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Royal Caribbean Cruises Ltd — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Royal Caribbean Cruises Ltd trades at $281 (market cap $75.70B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 35.5× ADMA Biologics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | RCL | |
|---|---|---|
Market Cap | $2.13B | $75.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $365.84 |
52-Week Low | $7.60 | $246.71 |
Enterprise Value | $2.20B | $96.98B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Royal Caribbean (RCL) trades at $282.26, down 4.74% on the day, showing bearish technical momentum but maintaining strong fundamentals. The company reported robust Q1 2026 earnings of $3.60 per share, beating expectations, with revenue growth accelerating from $16.5B in 2024 to $17.9B in 2025. Analyst consensus remains positive with a $325.10 price target, though technical indicators signal near-term caution with support at $283.
RCL presents a compelling investment case with strong profitability (50.41% ROE) and consistent earnings beats, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current pullback near key support levels offers potential entry points for long-term investors seeking exposure to the recovering cruise industry with disciplined financial management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
